26
Growth Score
pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Zestagen is a Swiss biotechnology company developing light chain mAbs against Extracellular Heat Shock Protein-90 (ehsp90).
About the Company
Zestagen is a Swiss biotechnology company developing light chain mAbs against Extracellular Heat Shock Protein-90 (ehsp90). hsp90 is a validated pharmaceutical target. ehsp90 is implicated in cancer cell motility, migration and metastasis. It is detectable at the surface of several cancer cells but not of normal adult cells. Zestagen's mAbs
bind ehsp90 at the surface of cancer cells (but not normal cells) leading to significant inhibition of metastasis in preclinical cancer animal models. Unlike small molecule hsp90 inhibitors which do not discriminate between the extracellular and intracellular hsp90 pool, Zestagen’s mAbs are predicted to display a superior therapeutic index in cancer patients.
